Protease Inhibitor Formulation LB1148 clinical trials
How each study uses Protease Inhibitor Formulation LB1148 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Palisade Bio (2) · Leading BioSciences, Inc (2) · Newsoara Biopharma Co., Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Protease Inhibitor Formulation LB1148 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel ResectionCompletedPhase 2Palisade BioNCT02836470Written as LB1148How we know
- A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel ResectionTerminatedPhase 3Palisade BioNCT05470387Written as LB1148How we know
- LB1148 for Pulmonary Dysfunction Associated With COVID-19 PneumoniaWithdrawnPhase 2Leading BioSciences, IncNCT04390217Written as LB1148How we know
- Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative IleusCompletedPhase 2Newsoara Biopharma Co., Ltd.NCT05056935Written as LB1148How we know
- Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148TerminatedPhase 2Leading BioSciences, IncNCT02317549Written as LB1148How we know